BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 36799315)

  • 1. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
    Vranic S; Basu GD; Hall DW; Gatalica Z
    Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
    Tateo V; Marchese PV; Mollica V; Massari F; Kurzrock R; Adashek JJ
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
    Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
    Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current Status and Challenges in Tumor Agnostic Treatment].
    Komine K
    Gan To Kagaku Ryoho; 2023 Jun; 50(6):657-661. PubMed ID: 37317595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of histology-agnostic treatments in metastatic colorectal cancer.
    Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
    Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. If it's a target, it's a pan-cancer target: Tissue is not the issue.
    Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
    Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-Agnostic Cancer Therapy Approvals.
    Gouda MA; Subbiah V
    Surg Oncol Clin N Am; 2024 Apr; 33(2):243-264. PubMed ID: 38401908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving landscape of tissue-agnostic therapies in precision oncology.
    Subbiah V; Gouda MA; Ryll B; Burris HA; Kurzrock R
    CA Cancer J Clin; 2024 May; ():. PubMed ID: 38814103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
    Seligson ND; Knepper TC; Ragg S; Walko CM
    Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of tissue-agnostic approvals on management of primary brain tumors.
    Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
    Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for
    Gouda MA; Subbiah V
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e404770. PubMed ID: 37159870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
    Capdevila J; Awada A; F├╝hrer-Sakel D; Leboulleux S; Pauwels P
    Cancer Treat Rev; 2022 May; 106():102380. PubMed ID: 35305441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
    Zhou I; Plana D; Palmer AC
    Clin Cancer Res; 2024 Feb; 30(4):786-792. PubMed ID: 38109210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining and Targeting BRAF Mutations in Solid Tumors.
    Halle BR; Johnson DB
    Curr Treat Options Oncol; 2021 Feb; 22(4):30. PubMed ID: 33641072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
    Bernocchi O; Sirico M; Corona SP; Strina C; Milani M; Cappelletti MR; Ferrero G; Ziglioli N; Cervoni V; Macchiavelli A; Roviello G; Generali D
    Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33669326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
    Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
    Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.
    Rankin A; Johnson A; Roos A; Kannan G; Knipstein J; Britt N; Rosenzweig M; Haberberger J; Pavlick D; Severson E; Vergilio JA; Squillace R; Erlich R; Sathyan P; Cramer S; Kram D; Ross J; Miller V; Reddy P; Alexander B; Ali SM; Ramkissoon S
    Oncologist; 2021 Jan; 26(1):e153-e163. PubMed ID: 32918774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.